PhaseBio Pharmaceuticals, Inc(NASDAQ:PHAS) 
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical ...
Website: http://www.phasebio.com
Founded: 2002
Full Time Employees: 50 (May 2021)
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2024-04-03
P
O 0.00
H 0.00
L 0.00
C 0.00
V 1
10EMA
20EMA
60EMA
120EMA
250EMA